Uncover key drivers, emerging technologies, and competitive movements shaping the sarcopenia treatment market from 2026–2035 with trusted insights from The Business Research Company
What upper market value could the Sarcopenia Treatment Market reach by 2030 starting from 2026 levels?
The sarcopenia treatment market has experienced robust expansion in recent years. It is projected to increase from $3.72 billion in 2025 to $3.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The growth observed in the past can be attributed to an expanding elderly population, a heightened understanding of age-related muscle loss, the reliance on physical therapy and nutritional interventions, the restricted availability of approved drug therapies, and a rising occurrence of mobility-related disorders.
The sarcopenia treatment market is projected to experience substantial expansion over the upcoming years. Its valuation is set to reach $4.97 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.0%. Factors contributing to this growth during the projection period include the introduction of new pharmacological therapies, a heightened emphasis on prompt diagnosis and early intervention, increased healthcare expenditure directed towards elderly care, a surge in chronic illnesses impacting muscle well-being, and an increase in clinical trials focused on muscle regeneration. Key trends predicted for this period encompass the wider utilization of combined drug and exercise-based therapies, a greater uptake of dietary supplements in managing sarcopenia, an escalation in clinical investigations into myostatin inhibitors and anabolic substances, a higher incidence of sarcopenia diagnoses among older adults, and the broader incorporation of physical therapy into therapeutic approaches.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp
Which Drivers Are Influencing Long-Term Growth In The Sarcopenia Treatment Market?
The growing prevalence of malnutrition is projected to fuel the expansion of the sarcopenia treatment market moving ahead. Malnutrition encompasses insufficient, excessive, or imbalanced consumption of energy and nutrients, covering conditions such as undernutrition, as well as overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment addresses the concurrent presence of malnutrition and sarcopenia, particularly in older adults, by employing interventions like nutritional therapy and exercise, with the goal of enhancing muscle mass, strength, and overall nutritional well-being. For instance, in January 2025, the United States Department of Agriculture, a US-based government department, published a report stating that household food insecurity affected 17.9% of families with children in 2023, impacting approximately 6.5 million of these households. Consequently, the increase in malnutrition is propelling the expansion of the sarcopenia treatment market.
Which Segments Are Driving Activity In The Sarcopenia Treatment Market?
The sarcopenia treatment market covered in this report is segmented –
1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types
2) By Type: Primary Sarcopenia, Secondary Sarcopenia
3) By Route Of Administration: Oral, Parenteral, Enteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Protein Supplements: Whey Protein, Casein Protein, Soy Protein, Plant-Based Protein
2) By Vitamin B12 Supplements: Cyanocobalamin, Methylcobalamin
3) By Vitamin D And Calcium Supplements: Vitamin D2, Vitamin D3, Calcium Carbonate, Calcium Citrate
4) By Other Treatment Types: Exercise Programs, Hormone Replacement Therapy, Other Nutritional Interventions
What Trends Are Reshaping The Dynamics Of The Sarcopenia Treatment Market?
Major companies within the sarcopenia treatment market are increasingly focusing on developing diverse advanced clinical study options to ensure better treatment alternatives. A clinical study constitutes a systematic investigation carried out on human participants to assess the safety, effectiveness, and/or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a biotechnology company based in France, announced that it had received Food and Drug Administration (FDA) authorization to commence the SARA-31 Phase 3 study for sarcopenia. This study aims to evaluate the efficacy and safety of Sarconeos (BIO101) in treating sarcopenic patients who are at risk of motor disability. This research signifies a substantial advancement in both technological and pharmaceutical treatment approaches, potentially offering benefits in terms of efficacy and safety for individuals with severe sarcopenia. It is notably the first-ever Phase 3 study in sarcopenia and has obtained FDA authorization. The study is set to involve approximately 900 patients, all over 65 years old, diagnosed with sarcopenia, exhibiting slow walking speed, and reduced hand grip strength. Its primary endpoint will focus on assessing the risk of major mobility disability (MMD), along with measuring walking speed, hand grip strength, and patient-reported quality of life.
Which Major Firms Are Strengthening Their Position In The Sarcopenia Treatment Market?
Major companies operating in the sarcopenia treatment market are Pfizer Inc, F Hoffmann La Roche, Merck Sharp And Dohme Corp, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, Abbott Laboratories Inc, GlaxoSmithKline plc, Eli Lilly And Company, BASF SE, Nestle Health Science, Haleon Group Of Companies, DSM, Amway Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt Ltd, Nutrafill
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report
Which Region Is Anticipated To See The Fastest Growth In The Sarcopenia Treatment Market?
North America was the largest region in the sarcopenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Sarcopenia Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13926&type=smp
Browse Through More Reports Similar to the Global Sarcopenia Treatment Market 2026, By The Business Research Company
Vulvodynia Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report
Sarcoma Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report
Congenital Diaphragmatic Hernia Drugs Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
